narrow-moat vertex sale soar symdeko
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim
price data apr
rate updat apr
currenc amount express
methodolog valu compani
vertex first-quart result slightli ahead
expect compani strong portfolio cystic
fibrosi therapi continu support narrow econom
moat total product revenu million
last year driven reimburs price
agreement europ anticip symdeko
launch recent germani
symkevi would key driver year uptak
first quarter much better expect
maintain fair valu estim per share
narrow-moat vertex would advis investor
wait wider margin safeti medium uncertainti
kalydeco address small portion cystic
fibrosi popul monotherapi saw slight decreas
sale last year contribut
million orkambi sale million
last year off-set growth
symdeko cover similar popul offer
attract safeti profil symdeko contribut
million sale significantli million last year
sequenti maintain
estim product revenu billion
near higher end guidanc oper expens
track expect maintain full-
year estim billion oper expens
midpoint manag guidanc
first quarter beat consensu top bottom
line guidanc take account possibl
reimburs agreement major countri still
wait hear agreement england franc
negoti on-going pleas
hear agreement pediatr patient sweden
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko cystic fibrosi addit sever pipelin candid
target market vertex pipelin also includ therapi cancer
pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
also wait hear triplet combin
therapi vertex choos file regulatori approv
approv cystic fibrosi patient heterozyg
address patient popul
cystic fibrosi patient
approv april vertex receiv first approv
cystic fibrosi infant kalydeco expand
address patient popul vertex reach
therapi expect addit label expans year
young age group could increas elig
popul patient world-wide
top-lin phase result vertex triplet
regimen releas eye vertex strategi shift
develop cystic fibrosi new indic
addit studi pain compani on-going earli
research antitrypsin defici gene edit
studi sickl cell diseas beta thalassemia
preclin work focal segment glomerulosclerosi
like focu lucr rare diseas high unmet
need competitor along develop
vy indic howev vertex research
develop strategi histor success
cystic fibrosi portfolio develop hous
early-stag pipelin candid outsid cystic
fibrosi materi contribut top-lin
project medium term compani complet
quarter billion cash equival
expect reinvest pipelin
potenti busi develop year vertex look
new market opportun outsid cystic fibrosi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
